undamentalytics Newsletter
Sign in

Charles River Laboratories income statement

In fiscal 2025, Charles River Laboratories reported revenue of $4.02bn, down 0.9% on the year before, operating income of $25.2m (a 0.6% margin) and net income of −$144m, or −$2.91 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2009Dec 20092010Dec 20102011Dec 20112012Dec 20122013Dec 20132014Dec 20142015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue1,1721,1331,1431,1301,1661,2981,3631,6811,8582,2662,6212,9243,5403,9764,1294,0504,0153,999
Selling, general and administrative228232199208226269300365371444518529620665748751743762
Operating income170−2991741661511782062382883313514335906516172272590
Interest expense2235433321121528306461867459137126107106
Provision for credit losses———————————627————
Income before tax152−33413313013817819522329728230444748162358193−100—
Income tax40017283348436717154508282130101684353
Net income114−3371109710312714915512322625236439148647522−144−238
Diluted EPS$1.74−$5.38$2.14$2.01$2.12$2.66$3.13$3.23$2.54$4.62$5.07$7.20$7.60$9.48$9.22$0.20−$2.91−$4.89
Diluted shares (average)66m63m51m48m48m48m48m48m49m49m50m51m51m51m51m52m50m49m
EBITDA260−205260247248274301364419493549668855955931589428388

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: CRL vs MTDCRL vs ILMNBRKR vs CRLCRL vs WAT

More: Life Sciences Tools & Services stocks compared, Health Care sector, rankings of US companies

Figures from Charles River Laboratories's SEC filings (10-K and 10-Q), retrieved October 20, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Charles River Laboratories.